Neuropeptide y receptor antagonists

IDrugs

Volumn 4, Issue 8, 2001, Pages 920-927

  Hammond, Marlys ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008924476     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. King PJ, Williams G: Role of ARC NPY neurons in energy homeostasls. Drug News Perspect (1998) 11:402-410. • Good review of central NPY its putative role in obesity and energy homeostasis.
2. 218:7-22. • Excellent review of NPY and receptor subtypes.
3. Lundberg JM, Tatemoto K: Pancreatic polypeptide family (APP, BPP, NPY, and PYY) In relation to sumpathelic vasoconstriction resistant to a-adrenoceptor blockade. Ada Physiol Scand (1982) 116:393-402.
4. Stanley BG, Leibowitz SF: Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Ute Sei (1984)35:2635-2642. • First report of the orexigenic effects of NPY.
5. Rohner-Jeanrenaud F: Hormonal regulation of energy partitioning. Int J Obes (2000) 24:S4-S7.
6. Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS: Neuropeptide Y sectretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Nat Acad Sei USA (1991) 88:10931-10935.
7. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B: Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology (1993) 133:1753-1758.
8. Vettor R, Zarjevski N, Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B: Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia (1994) 37:1202-1208.
9. Erickson JC, Clegg KE, Palmiter RD: Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature (1996)381:415-418. • Report of the NPY knockout phenotype.
10. Egawa M, Yoshimatsu H, Bray GA: Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am JP/iys/o/(1991) 260:R328-R334.
11. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M: Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc NatlAcad Sd USA ( 1998) 95:15659-15664. • Report of Y, knockout mice.
12. Naveilhan P, Hassani H, Canals JM, Ekstrand AJ, Larefalk A, Chhajlani V, Arenal E, Gedda K, Svensson L, Thoren P, Emfors P: Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nature Med (1999) 5:1188-1193. • Report of Y, knockout mice.
13. Marsh DJ, Hollopeter G, Käfer KE, Palmiter RD: Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nature Med (1998) 4:718-721. • Report of Ys knockout mice.
14. Kanatani A, Masahiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil DJ, Van der Ploeg LHT, Saga Y, Nishimura S, lhara M: Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptordeficient, and Y5 receptor-deficient mice. Endocrinology (2000) 141:1011-1016.
15. Ishihara A, Tanaka T, Kanatani A, Fukami T, lhara M, Fukuroda T: A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats. Am J Physio! (1998) 274:R1500-R1503. • First report of a selective V, antagonist and its effects on food intake.
16. Kanatani A, Kanno T, Ishihara A, Hata M, Sakuraba A, Tanaka T, Tsuchiya Y, Mase T, Fukuroda T, Fukami T, lhara M: The novel neuropeptide Y Y1 receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophvs Research Commun (1999) 266:88-91. • First report of an orally bioavailable Y, antagonist.
17. Criscione L, Rigollier P, BatzI-Hartmann C, Rüeger H, Stricker-Krongrad A, Wyss P, Brunner L, Whitebread S,-Yamaguchi Y, Gerald C, Heurich RO, Walker MW, Chiesi M, Schilling W, Hofbauer KG, Levens N: Food Intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y, receptor. J Clin Invest (1998) 102:2136-2145. • First report of a Y, antagonist suppressing food intake.
18. 25:84-94.
19. Kanatani A, Ishihara A, Isaawa H, Nakamura K, Okamoto O, Hidaka M, Ito J, Takahiro F, MacNeil DJ, Van der Ploeg LHT, Ishii Y, Okabe T, Fukami T, lhara M: L-152,804: Orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Research Commun (2000) 272:169-173.
20. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberiein W, Roudolf K: BIIE0246: A selective and high affinity neuropeptide Y Y, receptor antagonist. Eur J Pharmacol (1999)384:R3-R5. • First report of a selective Y, antagonist.
21. Rudolf K, Ebertein W, Engel W, Wieland HA, Willim KD, Entzeroth M, Weinen W, Beck-Sickinger AG, Doods HN: The first highly potent and selective non-peptide neuropeptide Y Y, receptor antagonist: BIBP 3226. Eur J Pharmacol (1994) 271:R11-R13. • First report of a selective, non-peptide Y, antagonist.
22. Carpino PA: Patent focus on new anti-obesity agents: September 1999 - February 2000. Exp Opin Ther Pat (2000) 10:819-831.
23. Zimânyi IA, Poindexter GS: NPY-Ergic agents for the treatment of obesity. Drug Dev Res (2000) 51:94-111.
24. Norman MH, Chen N, Chen Z, Fotsch C, Hale C, Han N, Hurt R, Jenkins T, Kincaid J, LJu L, Lu Y, Moreno O, Santora VJ, Sonnenberg JD, Karbon W: Structure-activity relationships of a series of pyrrolo[3,2-cf]pyrimidine derivatives and related compounds as neuropeptide YS receptor antagonists. J Meet Chem (2000) 43:42884312. to patent literature
25. GARVAN INSTITUTE OF MEDICAL RESEARCH, AUSTRALIA (Herzog H): Protein and cDNA sequences encoding human and mouse neuropeptide Y receptors (NPY-Y7), and uses thereof in drug screening assays. WO-00000606 (2000)
26. EAST CAROLINA UNIVERSITY (Nyce JW, Leonard SA): Neuropeptide Y analogues, compositions and methods of lowering blood pressure. US-06075009 (2000)
27. UNIVERSITY OF CINCINNATI (Balasubramanium A, Chance WT): Compounds for control of blood pressure, cardiovascular response, libido, and circadian rhythm. US-06013633 (2000)
28. DR KARLTHOMAE GMBH (Engel W, Eberlein W, Doods H, Wieland H-A, Willim K-D, Entzeroth M, Weinen W): Amino acid derivatives, pharmaceutically active compositions containing the compounds and processes for preparing them. US-06114390 (2000)
29. DR KARL THOMAE GMBH (Eberlein W, Engel W, Rudolf K, Doods H, Wieland H-A, Willim K-D): Amino acid derivatives, medicaments containing said compounds and methods of producing said compounds. US-06040289 (2000)
30. ASTRA AB (Bergman N-A, D'Ambra T, Pilling G): New NPY antagonists. WO-09915498(1999)
31. ASTRAZENECA AB (Antonsson T, Bergman N-A, Unschoten M, Westertund C): New NPY antagonists. WO-00102364 (2001)
32. NEUROGEN CORP (Blum CA, DeSimone R, Hutchison A, Peterson JM): Certain amldo- and amino-substituted benzylamine derivatives: a new class of neuropeptide Y1 specific ligands. US-06133265 (2000)
33. PFIZER INC (Peterson JM, Blum CA, Cai G, Hutchison A): Certain substituted benzylamine derivatives: a new class of neuropeptide Y1 specific ligands. WO-09640660 (1996)
34. BRISTOL-MYERS SQUIBB Co (Sit S-Y, Huang Y): Dihydropyrazine derivatives as NPY antagonists. US-06177429 (2001)
35. BRISTOL-MYERS SQUIBB Co (Poindexter G, Swann TR, Bruce MA, Morton MA, Huang Y, Sit S-Y, Breitenbucher JG): Dihydropyridine NPY antagonists: cyanoguanidine derivatives. WO-09854136 (1998)
36. MERCK & Co INC; BANYU PHARMACEUTICAL Co LTD (Gao Y-D, MacNeil DJ, Yang L, Morin NR, Fukami T, Kanatani A, Fukuroda T, Ishii Y, Morin M): Spiro-indolines as Y5 receptor antagonists. WO-00027845 (2000)
37. BANYU PHARMACEUTICAL Co LTD (Fukami T, Kanatani A, Ishihara A, Ishii Y, Takahashi T, Haga Y, Sakamoto T, Itoh T): Novel splro compounds. WO-00114376 (2001)
38. BRISTOL-MYERS SQUIBB Co (Poindexter G, Antal I, Guipponi LM, Stoffel RH, Bnjce M): NPY antagonists: spiroisoquinolinone derivatives. WO-00113917 (2001)
39. ASTRAZENECA UK LTD (Block MH, Donald SC, Foote K, Schofield P, Marsham PR): Carbazole derivatives and their use as neuropeptide Y5 receptor antagonists. WO-00107409 (2001)
40. BAYER CORP (Connell RD Lease TG, Ladouceur GH, Osterhout MH): Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists. US-06048900 (2000)
41. PFIZER INC (Dow RL, Hammond M): 4-Aminopyrrole{3,2-d)pyrimidines as neuropeptide Y receptor antagonists. US-06187778 (2001)
42. AMGEN INC (Norman MH, Chen N, Han N, Liu 1_ Hurt CR, Fotsch CH, Jenkins TJ, Moreno OA): Bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists. WO-09940091 (1999)
43. ORTHO-MCNEIL PHARMACEUTICAL INC (Dax SL, Lovenberg TW, Baxter EW, Carson JR, Ludovic! DW, Youngman MA): NAralkylaminotetralins as ligands for the neuropeptide Y receptor. WO-00020376 (2000)
44. ORTHO-MCNEIL PHARMACEUTICAL INC (Dax SL, McNally J): 3a,4,5,9bTetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders. WO-00068197 (2000)
45. ORTHO-MCNEIL PHARMACEUTICAL INC (Dax SL, McNally J, Youngman MA): Amlne and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. WO-00109120 (2001)
46. NEUROGEN CORP; PFIZER INC (Thurkauf A, Yuan J, Hutchison A, Blum CA, Elliot RL, Hammond M): Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives. US-06121260 (2000)
47. PFIZER PRODUCTS INC (Elliott RL, Hammond M, Hank RF): Compounds for the treatment of obesity. WO-00066578 (2000)
48. BANYU PHARMACEUTICAL Co LTD (Fukami T, Fukuroda T, Kanatani A, lhara M): Aminopyrazole derivatives. US-06166038 (2000)
49. BANYU PHARMACEUTICAL Co LTD (Fukami T, Fukuroda T, Kanatani A, lhara M): Urea derivatives. US-06043246 (2000)
50. BANYU PHARMACEUTICAL Co LTD (Fukami T, Fukuroda T, Kanatani A, lhara M): Pyrazole derivatives. US-06057335 (2000)
51. BANYU PHARMACEUTICAL Co LTD (Fukami T, Fukuroda T, Kanatani A, lhara M): Aminopyrazole derivatives. US-06180653 (2001)
52. ORTHO-MCNEIL PHARMACEUTICAL INC (Kordik CP, Lovenberg TW, Reitz AB): Pyrazole carboxamides useful for the treatment of obesity and other disorders. WO-00069849 (2000)
53. SYNAPTIC PHARMACEUTICAL CORP (Marzabadi MR, Wong WC, Noble SA): Selective NPY (Y5) antagonists (tricyclics). US-06124331 (2000)
54. SYNAPTIC PHARMACEUTICAL CORP (Marzabadi MR, Wong WC, Noble SA, Desai MN): Selective NPY (Y5) antagonists. WO-00064880 (2000)
55. SYNAPTIC PHARMACEUTICAL CORP; NOVARTIS AG (Marzabadi MR, Wong WC, Noble SA, Buhlmayer P, Rueger H, Yamaguchi Y, Schilling W): Selective NPY (Y5) antagonists. WO-00102379 (2001)
56. ADIR ET Co (Fauchere J-L, Ortuno J-C, Duhault J, Boutin JA, Levens N): Noveaux composes aminotriazcles, leur procède de preparation et les compsitions pharmaceutiques qui les contiennent EP-01044970(2000)
57. PFIZER PRODUCTS INC (Carpino PA, Hank RF, Hammond M): Amlde derivatives useful as neuropeptide Y (NPY) antagoniste. EP01033366 (2000)